Preoperative neoadjuvant targeted therapy remodels intra-tumoral heterogeneity of clear-cell renal cell carcinoma and ferroptosis inhibition induces resistance progression
- 18 May 2024
- journal article
- research article
- Published by Elsevier in Cancer Letters
- Vol. 593, 216963
Abstract
No abstract availableKeywords
This publication has 53 references indexed in Scilit:
- Neoadjuvant Nivolumab in Patients with High-risk Nonmetastatic Renal Cell CarcinomaEuropean Urology Oncology, 2021
- Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinomaCancer Cell, 2021
- Progressive immune dysfunction with advancing disease stage in renal cell carcinomaCancer Cell, 2021
- Single-cell sequencing links multiregional immune landscapes and tissue-resident T cells in ccRCC to tumor topology and therapy efficacyCancer Cell, 2021
- Neoadjuvant and adjuvant immunotherapy in renal cell carcinomaWorld Journal of Urology, 2021
- Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis BlockadeCancer Cell, 2020
- Gankyrin is a novel biomarker for disease progression and prognosis of patients with renal cell carcinomaEBioMedicine, 2019
- Single-Cell Transcriptomic Analysis of Primary and Metastatic Tumor Ecosystems in Head and Neck CancerCell, 2017
- Safety and Efficacy of Pazopanib Therapy Prior to Planned Nephrectomy in Metastatic Clear Cell Renal CancerJAMA Oncology, 2016
- Regulation of Ferroptotic Cancer Cell Death by GPX4Cell, 2014